SkinBioTherapeutics will “continue to be flexible enough to adapt to opportunities”

SkinBioTherapeutics PLC (AIM:SBTX) chief executive Stuart Ashman speaks to Proactive after announcing the raising of £2.5mln via a placing of new shares. He reveals what the company intends to do with the new funding, that may be augmented by a further £1mln from a retail offer.

Ashman says that SkinBioTherapeutics “has always been and always will continue to be flexible enough to adapt to opportunities as and when they come [its] way.”

#ProactiveInvestors #skinbiotherapeutics #health #medicine #biotech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews